Pharmacyclics Inc (PCYC) 261.25 $PCYC Market ov
Post# of 273257
Posted On: 09/03/2016 7:09:51 AM
Pharmacyclics Inc (PCYC) 261.25 $PCYC
Market overview - Global Pharmacyclics, Inc. Market Report Product Pipeline Review 2015 - By Acute Market Reports
M2 - Fri Feb 05, 7:02AM CST
'PHARMACYCLICS, INC. - Product Pipeline Review - 2015', provides an overview of the PHARMACYCLICS, INC.'s pharmaceutical research and development focus.
PCYC: 261.25 (+1.70)
Neuroblastoma - Pipeline Review, H2 2015
M2 - Thu Jan 28, 5:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/lzkrbt/neuroblastoma) has announced the addition of the "Neuroblastoma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Neuroblastoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Neuroblastoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Neuroblastoma Overview - Therapeutics Development - Pipeline Products for Neuroblastoma - Overview - Pipeline Products for Neuroblastoma - Comparative Analysis - Neuroblastoma - Therapeutics under Development by Companies - Neuroblastoma - Therapeutics under Investigation by Universities/Institutes - Neuroblastoma - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Neuroblastoma - Products under Development by Companies - Neuroblastoma - Products under Investigation by Universities/Institutes - Neuroblastoma - Companies Involved in Therapeutics Development - Ability Pharma, SL - Acetylon Pharmaceuticals, Inc. - Advanced Accelerator Applications SA - Ampio Pharmaceuticals, Inc. - APEIRON Biologics AG - AstraZeneca Plc - ATLAB Pharma SAS - Bellicum Pharmaceuticals, Inc. - Bexion Pharmaceuticals, LLC. - BioLineRx, Ltd. - Bionucleon Srl - Biotec Pharmacon ASA - Cebiotex, S.L. - Celgene Corporation - Chugai Pharmaceutical Co., Ltd. - Cleveland BioLabs, Inc. - CureFAKtor Pharmaceuticals, LLC - Cyclacel Pharmaceuticals, Inc. - DEKK-TEC, Inc. - Errant Gene Therapeutics, LLC - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline Plc - Ignyta, Inc. - Juno Therapeutics Inc. - Lindis Biotech GmbH - MabVax Therapeutics Holdings, Inc. - MEI Pharma, Inc. - Merck & Co., Inc. - Merrimack Pharmaceuticals, Inc. - Novartis AG - Novogen Limited - Pharmacyclics, Inc. - Pono Pharma - Progenics Pharmaceuticals, Inc. - Recombio S.L For more information visit http://www.researchandmarkets.com/research/lz...roblastoma
MBVX: 5.09 (+0.11), PCYC: 261.25 (+1.70), AMPE: 0.85 (-0.01), GSK: 44.26 (+1.28), MEIP: 1.76 (+0.02), AAAP: 34.63 (+0.22), MACK: 4.53 (-0.06), PGNX: 5.96 (-0.18), BLCM: 17.24 (-0.23), CYCC: 5.71 (unch), RXDX: 5.90 (+0.02), MRK: 62.98 (+0.08), AZN: 33.31 (+0.71), JUNO: 28.44 (-0.85), CBLI: 1.86 (-0.13), NVS: 79.38 (+1.11), CELGZ: 1.18 (+0.05)
Epithelial Ovarian Cancer - Pipeline Review, H2 2015
M2 - Thu Dec 17, 4:28AM CST
Research and Markets (http://www.researchandmarkets.com/research/62vzjr/epithelial) has announced the addition of the "Epithelial Ovarian Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Epithelial Ovarian Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Epithelial Ovarian Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - 35 of the 60 Companies Featured in this Pipeline Review - AbbVie Inc. - Acceleron Pharma, Inc. - Adaptimmune Limited - Amgen Inc. - Ascenta Therapeutics, Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - Bayer AG - Bionomics Limited - Celsion Corporation - Cerulean Pharma, Inc. - Clovis Oncology, Inc. - Dr. Reddy's Laboratories Limited - EirGenix Inc. - Eisai Co., Ltd. - Genor BioPharma Co., Ltd. - Glycotope GmbH - Hetero Drugs Limited - ImmunoGen, Inc. - Immunotope, Inc. - Incyte Corporation - Innate Immunotherapeutics Limited - Johnson & Johnson - Mabion SA - MabVax Therapeutics Holdings, Inc. - MedImmune, LLC - Merck & Co., Inc. - Millennium Pharmaceuticals, Inc. - Mycenax Biotech Inc. - Novartis AG - Pfizer Inc. - Pharma Mar, S.A. - Pharmacyclics, Inc. - Prima BioMed Ltd. - Tesaro, Inc. For more information visit http://www.researchandmarkets.com/research/62vzjr/epithelial
MBVX: 5.09 (+0.11), PCYC: 261.25 (+1.70), TSRO: 84.87 (+0.52), CERU: 1.02 (unch), PFE: 34.77 (+0.09), INCY: 82.02 (+1.21), IMGN: 2.75 (-0.05), AMGN: 169.77 (-0.36), JNJ: 119.32 (+0.24), CLSN: 1.20 (-0.02), CLVS: 23.40 (-0.19), MRK: 62.98 (+0.08), AZN: 33.31 (+0.71), ABBV: 64.12 (+0.09), NVS: 79.38 (+1.11), XLRN: 30.84 (+0.59)
Merger & Acquisition ETFs: Will 2016 Replicate 2015?
Zacks Equity Research - Zacks Investment Research - Tue Dec 15, 11:50AM CST
ETFs to play the winning momentum of merger and acquisitions in 2015 globally.
PCYC: 261.25 (+1.70), BRCM: 54.67 (+0.17), PFE: 34.77 (+0.09), ABBV: 64.12 (+0.09), MNA: 28.98 (+0.09), NXPI: 88.15 (+0.20), FSL: 36.53 (-1.53), HSP: 89.95 (-0.01), AVGO: 173.11 (-3.98), CSMA: 20.50 (+1.27), MRGR: 36.11 (unch)
Ergomed Ups the Ante for CEL-SCI
ACCESSWIRE - Wed Oct 21, 8:00AM CDT
NEW YORK, NY / ACCESSWIRE / October 21, 2015 / Cancer immunotherapy company CEL-SCI Corp. (NYSE MKT: CVM) is thriving. Ergomed, a multinational Contract Research Organization (CRO) with a pristine reputation and the confidence in CEL-SCI's lead drug Multikine to make a huge upfront $10 million investment, recently raised the ante 20% - to $12 million. The deal was done under the same terms first put in place that calls for only a single-digit royalty on potential sales. This clearly shows Ergomed's confidence not only in the likelihood of Multikine being approved, but also in the large revenue potential of the cancer immunotherapy drug.
MNK: 72.42 (-3.17), INO: 9.08 (-0.06), SNTA: 0.34 (+0.07), PCYC: 261.25 (+1.70), ADRO: 14.49 (+0.27), CVM: 0.43 (-0.05), IMGN: 2.75 (-0.05), CLLS: 26.40 (unch), AEZS: 3.53 (-0.03), JUNO: 28.44 (-0.85), BMY: 56.35 (-0.41)
Hodgkin Lymphoma Pipeline Review, H2 2015 - 38 Companies & 57 Drug Profiles
M2 - Wed Sep 23, 4:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/x5k9pd/hodgkin_lymphoma) has announced the addition of the "Hodgkin Lymphoma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Hodgkin Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hodgkin Lymphoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development (Partial List) - 4SC AG - Acetylon Pharmaceuticals, Inc. - Actinium Pharmaceuticals, Inc. - ADC Therapeutics Sarl - Affimed Therapeutics AG - Aptose Biosciences Inc. - Arbutus Biopharma Corporation - AVEO Pharmaceuticals, Inc. - Bellicum Pharmaceuticals, Inc. - Biogenomics Limited - Bristol-Myers Squibb Company - Celgene Corporation - Cell Medica Limited - Cellular Biomedicine Group, Inc. - Constellation Pharmaceuticals, Inc. - Curis, Inc. - Gamida Cell Ltd. - Gilead Sciences, Inc. - Incyte Corporation - Johnson & Johnson - Merck & Co., Inc. - Millennium Pharmaceuticals, Inc. - Mirati Therapeutics Inc. - Molecular Templates Inc. - NantKwest, Inc. - Novartis AG - Ono Pharmaceutical Co., Ltd. - Pfizer Inc. - Pharmacyclics, Inc. - Philogen S.p.A. - Seattle Genetics, Inc. - Selvita SA - Sigma-Tau S.p.A. - TG Therapeutics, Inc. - Theravectys SA Drug Profiles (Partial List) - abexinostat hydrochloride - Drug Profile - acalisib - Drug Profile - ADCT-301 - Drug Profile - AFM-13 - Drug Profile - Alocrest - Drug Profile - aNK Program - Drug Profile - APTO-253 - Drug Profile - azacitidine - Drug Profile - BMS-986016 - Drug Profile - BPX-501 - Drug Profile - brentuximab vedotin - Drug Profile - CBM-C30.1 - Drug Profile - Cell Therapy to Target CD30 for Hodgkin and Non-Hodgkin Lymphomas - Drug Profile - Cell Therapy to Target GM-CSF for Hodgkin Lymphoma and Chronic Lymphocytic Leukemia - Drug Profile - Cell Therapy to Target LMP, BARF-1 and EBNA1 for EBV Associated Cancers and Infection - Drug Profile - Cell Therapy to Target LMP-1 and LMP-2 for Oncology and Infectious Diseases - Drug Profile - Cell Therapy to Target NY-ESO-1, MAGEA4, PRAME, Survivin and Synovial Sarcoma X for Oncology - Drug Profile - CMD-003 - Drug Profile - CPI-0610 - Drug Profile - CUDC-907 - Drug Profile - Dendritic Cell Therapy for Hodgkin Lymphoma and Non-Hodgkin Lymphoma - Drug Profile - INCB-40093 - Drug Profile - Indimitecan - Drug Profile - Indotecan hydrochloride - Drug Profile - interferon alfa-2b (recombinant) - Drug Profile - Iomab-B - Drug Profile - NSC-678515 - Drug Profile - panobinostat - Drug Profile - pembrolizumab - Drug Profile - pevonedistat hydrochloride - Drug Profile - procarbazine hydrochloride - Drug Profile - radretumab - Drug Profile - Recombinant Proteins for Melanoma and Hodgkin's Lymphoma - Drug Profile - TGR-1202 - Drug Profile - TKM-PLK1 - Drug Profile For more information visit http://www.researchandmarkets.com/research/x5...n_lymphoma
CRIS: 1.73 (+0.02), PCYC: 261.25 (+1.70), PFE: 34.77 (+0.09), INCY: 82.02 (+1.21), TGTX: 6.53 (+0.02), BMY: 56.35 (-0.41), ABUS: 3.76 (-0.03), JNJ: 119.32 (+0.24), APTO: 2.20 (+0.16), ATNM: 1.70 (-0.06), BLCM: 17.24 (-0.23), SGEN: 44.78 (-0.12), GILD: 76.89 (-0.53), MRK: 62.98 (+0.08), AVEO: 0.90 (-0.01), MRTX: 5.15 (-0.03), CBMG: 13.94 (-0.55), NVS: 79.38 (+1.11), CELGZ: 1.18 (+0.05)
Global Nasopharyngeal Cancer Pipeline Review 2015
M2 - Tue Sep 08, 5:42AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2qlv6j/nasopharyngeal) has announced the addition of the "Nasopharyngeal Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Nasopharyngeal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Nasopharyngeal Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Ambrx, Inc. - AVEO Pharmaceuticals, Inc. - BioDiem Ltd - Celgene Corporation - Cyclacel Pharmaceuticals, Inc. - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline Plc - Merck & Co., Inc. - Otsuka Holdings Co., Ltd. - Pharmacyclics, Inc. - Theravectys SA - Zhejiang BetaPharma Co., Ltd. For more information visit http://www.researchandmarkets.com/research/2q...pharyngeal
PCYC: 261.25 (+1.70), CYCC: 5.71 (unch), AMBX: (), MRK: 62.98 (+0.08), AVEO: 0.90 (-0.01), GSK: 44.26 (+1.28), CELGZ: 1.18 (+0.05)
Pharmacyclics Up 77.4% Since SmarTrend Uptrend Call (PCYC)
Comtex SmarTrend(R) - Wed Jul 08, 11:30AM CDT
SmarTrend identified an Uptrend for Pharmacyclics (NASDAQ
CYC) on January 13th, 2015 at $147.27. In approximately 6 months, Pharmacyclics has returned 77.40% as of today's recent price of $261.25.
PCYC: 261.25 (+1.70)
Uptrend Call Working As Pharmacyclics Stock Rises 77.4% (PCYC)
Comtex SmarTrend(R) - Wed Jul 01, 9:44AM CDT
SmarTrend identified an Uptrend for Pharmacyclics (NASDAQ CYC) on January 13th, 2015 at $147.27. In approximately 6 months, Pharmacyclics has returned 77.40% as of today's recent price of $261.25.
PCYC: 261.25 (+1.70)
Burkitt Lymphoma Therapeutics Pipeline Review, H1 2015 - 6 Companies & 10 Drug Profiles
M2 - Wed Jun 24, 10:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/896pmt/burkitt_lymphoma) has announced the addition of the "Burkitt Lymphoma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Burkitt Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Burkitt Lymphoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AstraZeneca PLC - Constellation Pharmaceuticals, Inc. - Karyopharm Therapeutics, Inc. - Millennium Pharmaceuticals, Inc. - Pharmacyclics, Inc. - Seattle Genetics, Inc. Drug Profiles - alisertib - AZD-6738 - denintuzumab mafodotin - ibrutinib - Monoclonal Antibody Conjugated to Target CD20 for Leukemia and Burkitt Lymphoma - selinexor - SH-7129 - SH-7133 - SH-7139 - Small Molecules to Inhibit BET for Cancer For more information visit http://www.researchandmarkets.com/research/89...t_lymphoma
PCYC: 261.25 (+1.70), SGEN: 44.78 (-0.12), AZN: 33.31 (+0.71), KPTI: 10.62 (-0.48)
Pharmacyclics Has Returned 77.4% Since SmarTrend Recommendation (PCYC)
Comtex SmarTrend(R) - Wed Jun 24, 9:19AM CDT
SmarTrend identified an Uptrend for Pharmacyclics (NASDAQ CYC) on January 13th, 2015 at $147.27. In approximately 5 months, Pharmacyclics has returned 77.40% as of today's recent price of $261.25.
PCYC: 261.25 (+1.70)
Pharmacyclics, Inc. (PCYC) - Financial and Strategic SWOT Analysis Review
M2 - Fri Jun 12, 3:54AM CDT
PCYC: 261.25 (+1.70)
T-Cell Leukemia Pipeline Review, H1 2015 - 14 Companies & 20 Drug Profiles
M2 - Thu Jun 11, 6:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2b68lm/tcell_leukemia) has announced the addition of the "T-Cell Leukemia - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for T-Cell Leukemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for T-Cell Leukemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Applied Immune Technologies Ltd - Astellas Pharma Inc. - Bristol-Myers Squibb Company - Celgene Corporation - iDD biotech SAS - Kyowa Hakko Kirin Co., Ltd. - MediGene AG - Nippon Kayaku Co., Ltd. - Pfizer Inc. - Pharmacyclics, Inc. - Sanofi - Stemline Therapeutics, Inc. - Theravectys S.A. - Tolero Pharmaceuticals, Inc. Drug Profiles - AGS-67E - alemtuzumab - Antibody to Inhibit HLA-A2 for Neurology, Infectious Diseases and T-Cell Leukemia - BMS-906024 - Cell Therapy to Target CD38 for cancer - IDD-003 - INA-01 - lenalidomide - MMIG-202 - mogamulizumab - Monoclonal Antibodies to Antagonize TCR for Leukemia and Autoimmune Disease - Monoclonal Antibody to Target CCR9 for T Lymphoblastic Leukemia - NK-314 - Oncolytic Virus to Target Glycoprotein gp160 for T-cell Leukemia - PCI-34051 - PF-03084014 - SL-101 - Synthetic Peptide for Oncology and Male health - THV-02 - TP-0903 For more information visit http://www.researchandmarkets.com/research/2b...l_leukemia
PCYC: 261.25 (+1.70), PFE: 34.77 (+0.09), BMY: 56.35 (-0.41), STML: 8.03 (-0.12), CELGZ: 1.18 (+0.05)
Waldenstrom Macroglobulinemia - Pipeline Review, H1 2015 - 18 Companies & 27 Drug Profiles
M2 - Wed Jun 10, 4:20AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8pl7hb/waldenstrom) has announced the addition of the "Waldenstrom Macroglobulinemia - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Waldenstrom Macroglobulinemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Waldenstrom Macroglobulinemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - arGEN-X BV - Bayer AG - Calithera Biosciences, Inc. - Celgene Corporation - Genmab A/S - Gilead Sciences, Inc. - Idera Pharmaceuticals, Inc. - Immune System Therapeutics Ltd. - Incyte Corporation - Karyopharm Therapeutics, Inc. - Merck KGaA - Millennium Pharmaceuticals, Inc. - Nimbus Therapeutics, LLC - Nordic Nanovector AS - Novartis AG - Onyx Pharmaceuticals, Inc. - Pharmacyclics, Inc. Drug Profiles - ACP-196 - ARGX-110 - Betalutin - carfilzomib - CB-839 - copanlisib - DI-B4 - everolimus - FV-162 - FV-214 - GS-9973 - ibrutinib - idelalisib - IMO-8400 - INCB-39110 - INCB-40093 - IST-1097 - ixazomib citrate - lenalidomide - ofatumumab - oprozomib - pevonedistat hydrochloride - sapanisertib - selinexor - Small Molecules to Inhibit IRAK4 for Immunology and Oncology - spebrutinib besylate - venetoclax For more information visit http://www.researchandmarkets.com/research/8p...aldenstrom
PCYC: 261.25 (+1.70), INCY: 82.02 (+1.21), IDRA: 1.92 (unch), GILD: 76.89 (-0.53), CALA: 3.08 (unch), ABBV: 64.12 (+0.09), NVS: 79.38 (+1.11), CELGZ: 1.18 (+0.05), KPTI: 10.62 (-0.48)
Shares of PCYC Up 77.4% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Tue Jun 09, 11:25AM CDT
SmarTrend identified an Uptrend for Pharmacyclics (NASDAQ CYC) on January 13th, 2015 at $147.27. In approximately 5 months, Pharmacyclics has returned 77.40% as of today's recent price of $261.25.
PCYC: 261.25 (+1.70)
Market overview - Global Pharmacyclics, Inc. Market Report Product Pipeline Review 2015 - By Acute Market Reports
M2 - Fri Feb 05, 7:02AM CST
'PHARMACYCLICS, INC. - Product Pipeline Review - 2015', provides an overview of the PHARMACYCLICS, INC.'s pharmaceutical research and development focus.
PCYC: 261.25 (+1.70)
Neuroblastoma - Pipeline Review, H2 2015
M2 - Thu Jan 28, 5:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/lzkrbt/neuroblastoma) has announced the addition of the "Neuroblastoma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Neuroblastoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Neuroblastoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Neuroblastoma Overview - Therapeutics Development - Pipeline Products for Neuroblastoma - Overview - Pipeline Products for Neuroblastoma - Comparative Analysis - Neuroblastoma - Therapeutics under Development by Companies - Neuroblastoma - Therapeutics under Investigation by Universities/Institutes - Neuroblastoma - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Neuroblastoma - Products under Development by Companies - Neuroblastoma - Products under Investigation by Universities/Institutes - Neuroblastoma - Companies Involved in Therapeutics Development - Ability Pharma, SL - Acetylon Pharmaceuticals, Inc. - Advanced Accelerator Applications SA - Ampio Pharmaceuticals, Inc. - APEIRON Biologics AG - AstraZeneca Plc - ATLAB Pharma SAS - Bellicum Pharmaceuticals, Inc. - Bexion Pharmaceuticals, LLC. - BioLineRx, Ltd. - Bionucleon Srl - Biotec Pharmacon ASA - Cebiotex, S.L. - Celgene Corporation - Chugai Pharmaceutical Co., Ltd. - Cleveland BioLabs, Inc. - CureFAKtor Pharmaceuticals, LLC - Cyclacel Pharmaceuticals, Inc. - DEKK-TEC, Inc. - Errant Gene Therapeutics, LLC - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline Plc - Ignyta, Inc. - Juno Therapeutics Inc. - Lindis Biotech GmbH - MabVax Therapeutics Holdings, Inc. - MEI Pharma, Inc. - Merck & Co., Inc. - Merrimack Pharmaceuticals, Inc. - Novartis AG - Novogen Limited - Pharmacyclics, Inc. - Pono Pharma - Progenics Pharmaceuticals, Inc. - Recombio S.L For more information visit http://www.researchandmarkets.com/research/lz...roblastoma
MBVX: 5.09 (+0.11), PCYC: 261.25 (+1.70), AMPE: 0.85 (-0.01), GSK: 44.26 (+1.28), MEIP: 1.76 (+0.02), AAAP: 34.63 (+0.22), MACK: 4.53 (-0.06), PGNX: 5.96 (-0.18), BLCM: 17.24 (-0.23), CYCC: 5.71 (unch), RXDX: 5.90 (+0.02), MRK: 62.98 (+0.08), AZN: 33.31 (+0.71), JUNO: 28.44 (-0.85), CBLI: 1.86 (-0.13), NVS: 79.38 (+1.11), CELGZ: 1.18 (+0.05)
Epithelial Ovarian Cancer - Pipeline Review, H2 2015
M2 - Thu Dec 17, 4:28AM CST
Research and Markets (http://www.researchandmarkets.com/research/62vzjr/epithelial) has announced the addition of the "Epithelial Ovarian Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Epithelial Ovarian Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Epithelial Ovarian Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - 35 of the 60 Companies Featured in this Pipeline Review - AbbVie Inc. - Acceleron Pharma, Inc. - Adaptimmune Limited - Amgen Inc. - Ascenta Therapeutics, Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - Bayer AG - Bionomics Limited - Celsion Corporation - Cerulean Pharma, Inc. - Clovis Oncology, Inc. - Dr. Reddy's Laboratories Limited - EirGenix Inc. - Eisai Co., Ltd. - Genor BioPharma Co., Ltd. - Glycotope GmbH - Hetero Drugs Limited - ImmunoGen, Inc. - Immunotope, Inc. - Incyte Corporation - Innate Immunotherapeutics Limited - Johnson & Johnson - Mabion SA - MabVax Therapeutics Holdings, Inc. - MedImmune, LLC - Merck & Co., Inc. - Millennium Pharmaceuticals, Inc. - Mycenax Biotech Inc. - Novartis AG - Pfizer Inc. - Pharma Mar, S.A. - Pharmacyclics, Inc. - Prima BioMed Ltd. - Tesaro, Inc. For more information visit http://www.researchandmarkets.com/research/62vzjr/epithelial
MBVX: 5.09 (+0.11), PCYC: 261.25 (+1.70), TSRO: 84.87 (+0.52), CERU: 1.02 (unch), PFE: 34.77 (+0.09), INCY: 82.02 (+1.21), IMGN: 2.75 (-0.05), AMGN: 169.77 (-0.36), JNJ: 119.32 (+0.24), CLSN: 1.20 (-0.02), CLVS: 23.40 (-0.19), MRK: 62.98 (+0.08), AZN: 33.31 (+0.71), ABBV: 64.12 (+0.09), NVS: 79.38 (+1.11), XLRN: 30.84 (+0.59)
Merger & Acquisition ETFs: Will 2016 Replicate 2015?
Zacks Equity Research - Zacks Investment Research - Tue Dec 15, 11:50AM CST
ETFs to play the winning momentum of merger and acquisitions in 2015 globally.
PCYC: 261.25 (+1.70), BRCM: 54.67 (+0.17), PFE: 34.77 (+0.09), ABBV: 64.12 (+0.09), MNA: 28.98 (+0.09), NXPI: 88.15 (+0.20), FSL: 36.53 (-1.53), HSP: 89.95 (-0.01), AVGO: 173.11 (-3.98), CSMA: 20.50 (+1.27), MRGR: 36.11 (unch)
Ergomed Ups the Ante for CEL-SCI
ACCESSWIRE - Wed Oct 21, 8:00AM CDT
NEW YORK, NY / ACCESSWIRE / October 21, 2015 / Cancer immunotherapy company CEL-SCI Corp. (NYSE MKT: CVM) is thriving. Ergomed, a multinational Contract Research Organization (CRO) with a pristine reputation and the confidence in CEL-SCI's lead drug Multikine to make a huge upfront $10 million investment, recently raised the ante 20% - to $12 million. The deal was done under the same terms first put in place that calls for only a single-digit royalty on potential sales. This clearly shows Ergomed's confidence not only in the likelihood of Multikine being approved, but also in the large revenue potential of the cancer immunotherapy drug.
MNK: 72.42 (-3.17), INO: 9.08 (-0.06), SNTA: 0.34 (+0.07), PCYC: 261.25 (+1.70), ADRO: 14.49 (+0.27), CVM: 0.43 (-0.05), IMGN: 2.75 (-0.05), CLLS: 26.40 (unch), AEZS: 3.53 (-0.03), JUNO: 28.44 (-0.85), BMY: 56.35 (-0.41)
Hodgkin Lymphoma Pipeline Review, H2 2015 - 38 Companies & 57 Drug Profiles
M2 - Wed Sep 23, 4:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/x5k9pd/hodgkin_lymphoma) has announced the addition of the "Hodgkin Lymphoma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Hodgkin Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hodgkin Lymphoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development (Partial List) - 4SC AG - Acetylon Pharmaceuticals, Inc. - Actinium Pharmaceuticals, Inc. - ADC Therapeutics Sarl - Affimed Therapeutics AG - Aptose Biosciences Inc. - Arbutus Biopharma Corporation - AVEO Pharmaceuticals, Inc. - Bellicum Pharmaceuticals, Inc. - Biogenomics Limited - Bristol-Myers Squibb Company - Celgene Corporation - Cell Medica Limited - Cellular Biomedicine Group, Inc. - Constellation Pharmaceuticals, Inc. - Curis, Inc. - Gamida Cell Ltd. - Gilead Sciences, Inc. - Incyte Corporation - Johnson & Johnson - Merck & Co., Inc. - Millennium Pharmaceuticals, Inc. - Mirati Therapeutics Inc. - Molecular Templates Inc. - NantKwest, Inc. - Novartis AG - Ono Pharmaceutical Co., Ltd. - Pfizer Inc. - Pharmacyclics, Inc. - Philogen S.p.A. - Seattle Genetics, Inc. - Selvita SA - Sigma-Tau S.p.A. - TG Therapeutics, Inc. - Theravectys SA Drug Profiles (Partial List) - abexinostat hydrochloride - Drug Profile - acalisib - Drug Profile - ADCT-301 - Drug Profile - AFM-13 - Drug Profile - Alocrest - Drug Profile - aNK Program - Drug Profile - APTO-253 - Drug Profile - azacitidine - Drug Profile - BMS-986016 - Drug Profile - BPX-501 - Drug Profile - brentuximab vedotin - Drug Profile - CBM-C30.1 - Drug Profile - Cell Therapy to Target CD30 for Hodgkin and Non-Hodgkin Lymphomas - Drug Profile - Cell Therapy to Target GM-CSF for Hodgkin Lymphoma and Chronic Lymphocytic Leukemia - Drug Profile - Cell Therapy to Target LMP, BARF-1 and EBNA1 for EBV Associated Cancers and Infection - Drug Profile - Cell Therapy to Target LMP-1 and LMP-2 for Oncology and Infectious Diseases - Drug Profile - Cell Therapy to Target NY-ESO-1, MAGEA4, PRAME, Survivin and Synovial Sarcoma X for Oncology - Drug Profile - CMD-003 - Drug Profile - CPI-0610 - Drug Profile - CUDC-907 - Drug Profile - Dendritic Cell Therapy for Hodgkin Lymphoma and Non-Hodgkin Lymphoma - Drug Profile - INCB-40093 - Drug Profile - Indimitecan - Drug Profile - Indotecan hydrochloride - Drug Profile - interferon alfa-2b (recombinant) - Drug Profile - Iomab-B - Drug Profile - NSC-678515 - Drug Profile - panobinostat - Drug Profile - pembrolizumab - Drug Profile - pevonedistat hydrochloride - Drug Profile - procarbazine hydrochloride - Drug Profile - radretumab - Drug Profile - Recombinant Proteins for Melanoma and Hodgkin's Lymphoma - Drug Profile - TGR-1202 - Drug Profile - TKM-PLK1 - Drug Profile For more information visit http://www.researchandmarkets.com/research/x5...n_lymphoma
CRIS: 1.73 (+0.02), PCYC: 261.25 (+1.70), PFE: 34.77 (+0.09), INCY: 82.02 (+1.21), TGTX: 6.53 (+0.02), BMY: 56.35 (-0.41), ABUS: 3.76 (-0.03), JNJ: 119.32 (+0.24), APTO: 2.20 (+0.16), ATNM: 1.70 (-0.06), BLCM: 17.24 (-0.23), SGEN: 44.78 (-0.12), GILD: 76.89 (-0.53), MRK: 62.98 (+0.08), AVEO: 0.90 (-0.01), MRTX: 5.15 (-0.03), CBMG: 13.94 (-0.55), NVS: 79.38 (+1.11), CELGZ: 1.18 (+0.05)
Global Nasopharyngeal Cancer Pipeline Review 2015
M2 - Tue Sep 08, 5:42AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2qlv6j/nasopharyngeal) has announced the addition of the "Nasopharyngeal Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Nasopharyngeal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Nasopharyngeal Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Ambrx, Inc. - AVEO Pharmaceuticals, Inc. - BioDiem Ltd - Celgene Corporation - Cyclacel Pharmaceuticals, Inc. - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline Plc - Merck & Co., Inc. - Otsuka Holdings Co., Ltd. - Pharmacyclics, Inc. - Theravectys SA - Zhejiang BetaPharma Co., Ltd. For more information visit http://www.researchandmarkets.com/research/2q...pharyngeal
PCYC: 261.25 (+1.70), CYCC: 5.71 (unch), AMBX: (), MRK: 62.98 (+0.08), AVEO: 0.90 (-0.01), GSK: 44.26 (+1.28), CELGZ: 1.18 (+0.05)
Pharmacyclics Up 77.4% Since SmarTrend Uptrend Call (PCYC)
Comtex SmarTrend(R) - Wed Jul 08, 11:30AM CDT
SmarTrend identified an Uptrend for Pharmacyclics (NASDAQ
CYC) on January 13th, 2015 at $147.27. In approximately 6 months, Pharmacyclics has returned 77.40% as of today's recent price of $261.25. PCYC: 261.25 (+1.70)
Uptrend Call Working As Pharmacyclics Stock Rises 77.4% (PCYC)
Comtex SmarTrend(R) - Wed Jul 01, 9:44AM CDT
SmarTrend identified an Uptrend for Pharmacyclics (NASDAQ
CYC) on January 13th, 2015 at $147.27. In approximately 6 months, Pharmacyclics has returned 77.40% as of today's recent price of $261.25. PCYC: 261.25 (+1.70)
Burkitt Lymphoma Therapeutics Pipeline Review, H1 2015 - 6 Companies & 10 Drug Profiles
M2 - Wed Jun 24, 10:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/896pmt/burkitt_lymphoma) has announced the addition of the "Burkitt Lymphoma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Burkitt Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Burkitt Lymphoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AstraZeneca PLC - Constellation Pharmaceuticals, Inc. - Karyopharm Therapeutics, Inc. - Millennium Pharmaceuticals, Inc. - Pharmacyclics, Inc. - Seattle Genetics, Inc. Drug Profiles - alisertib - AZD-6738 - denintuzumab mafodotin - ibrutinib - Monoclonal Antibody Conjugated to Target CD20 for Leukemia and Burkitt Lymphoma - selinexor - SH-7129 - SH-7133 - SH-7139 - Small Molecules to Inhibit BET for Cancer For more information visit http://www.researchandmarkets.com/research/89...t_lymphoma
PCYC: 261.25 (+1.70), SGEN: 44.78 (-0.12), AZN: 33.31 (+0.71), KPTI: 10.62 (-0.48)
Pharmacyclics Has Returned 77.4% Since SmarTrend Recommendation (PCYC)
Comtex SmarTrend(R) - Wed Jun 24, 9:19AM CDT
SmarTrend identified an Uptrend for Pharmacyclics (NASDAQ
CYC) on January 13th, 2015 at $147.27. In approximately 5 months, Pharmacyclics has returned 77.40% as of today's recent price of $261.25. PCYC: 261.25 (+1.70)
Pharmacyclics, Inc. (PCYC) - Financial and Strategic SWOT Analysis Review
M2 - Fri Jun 12, 3:54AM CDT
PCYC: 261.25 (+1.70)
T-Cell Leukemia Pipeline Review, H1 2015 - 14 Companies & 20 Drug Profiles
M2 - Thu Jun 11, 6:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2b68lm/tcell_leukemia) has announced the addition of the "T-Cell Leukemia - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for T-Cell Leukemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for T-Cell Leukemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Applied Immune Technologies Ltd - Astellas Pharma Inc. - Bristol-Myers Squibb Company - Celgene Corporation - iDD biotech SAS - Kyowa Hakko Kirin Co., Ltd. - MediGene AG - Nippon Kayaku Co., Ltd. - Pfizer Inc. - Pharmacyclics, Inc. - Sanofi - Stemline Therapeutics, Inc. - Theravectys S.A. - Tolero Pharmaceuticals, Inc. Drug Profiles - AGS-67E - alemtuzumab - Antibody to Inhibit HLA-A2 for Neurology, Infectious Diseases and T-Cell Leukemia - BMS-906024 - Cell Therapy to Target CD38 for cancer - IDD-003 - INA-01 - lenalidomide - MMIG-202 - mogamulizumab - Monoclonal Antibodies to Antagonize TCR for Leukemia and Autoimmune Disease - Monoclonal Antibody to Target CCR9 for T Lymphoblastic Leukemia - NK-314 - Oncolytic Virus to Target Glycoprotein gp160 for T-cell Leukemia - PCI-34051 - PF-03084014 - SL-101 - Synthetic Peptide for Oncology and Male health - THV-02 - TP-0903 For more information visit http://www.researchandmarkets.com/research/2b...l_leukemia
PCYC: 261.25 (+1.70), PFE: 34.77 (+0.09), BMY: 56.35 (-0.41), STML: 8.03 (-0.12), CELGZ: 1.18 (+0.05)
Waldenstrom Macroglobulinemia - Pipeline Review, H1 2015 - 18 Companies & 27 Drug Profiles
M2 - Wed Jun 10, 4:20AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8pl7hb/waldenstrom) has announced the addition of the "Waldenstrom Macroglobulinemia - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Waldenstrom Macroglobulinemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Waldenstrom Macroglobulinemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - arGEN-X BV - Bayer AG - Calithera Biosciences, Inc. - Celgene Corporation - Genmab A/S - Gilead Sciences, Inc. - Idera Pharmaceuticals, Inc. - Immune System Therapeutics Ltd. - Incyte Corporation - Karyopharm Therapeutics, Inc. - Merck KGaA - Millennium Pharmaceuticals, Inc. - Nimbus Therapeutics, LLC - Nordic Nanovector AS - Novartis AG - Onyx Pharmaceuticals, Inc. - Pharmacyclics, Inc. Drug Profiles - ACP-196 - ARGX-110 - Betalutin - carfilzomib - CB-839 - copanlisib - DI-B4 - everolimus - FV-162 - FV-214 - GS-9973 - ibrutinib - idelalisib - IMO-8400 - INCB-39110 - INCB-40093 - IST-1097 - ixazomib citrate - lenalidomide - ofatumumab - oprozomib - pevonedistat hydrochloride - sapanisertib - selinexor - Small Molecules to Inhibit IRAK4 for Immunology and Oncology - spebrutinib besylate - venetoclax For more information visit http://www.researchandmarkets.com/research/8p...aldenstrom
PCYC: 261.25 (+1.70), INCY: 82.02 (+1.21), IDRA: 1.92 (unch), GILD: 76.89 (-0.53), CALA: 3.08 (unch), ABBV: 64.12 (+0.09), NVS: 79.38 (+1.11), CELGZ: 1.18 (+0.05), KPTI: 10.62 (-0.48)
Shares of PCYC Up 77.4% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Tue Jun 09, 11:25AM CDT
SmarTrend identified an Uptrend for Pharmacyclics (NASDAQ
CYC) on January 13th, 2015 at $147.27. In approximately 5 months, Pharmacyclics has returned 77.40% as of today's recent price of $261.25. PCYC: 261.25 (+1.70)
(0)
(0)Scroll down for more posts ▼